By Editor • August 29, 2026 • 1 min read
In a promising development, Novartis' drug pacibekitug demonstrated significant reductions in inflammation during the Phase 2 TRANQUILITY study, presented at the European Society of Cardiology meeting in Munich.
Experts are now eager to see how the company plans to position this IL-6 targeting antibody as a cardiovascular treatment.
Source: www.statnews.com
By Editor • August 29, 2026 • 1 min read
Health journalists are raising awareness on measles, vaccinations, and healthcare policy as midterms approach.
Read moreBy Editor • August 28, 2026 • 1 min read
New research indicates that thousands of UK mothers develop undiagnosed PTSD after childbirth, often mistaken for postnatal depression.
Read moreBy Editor • August 28, 2026 • 1 min read
Whole Foods has escalated its guacamole and salsa recall due to salmonella contamination linked to jalapeños, affecting 32 states.
Read more
